ly2624803
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2008 (NCT01779830)
Timeline
Indications
Mechanism of action
- Histamine H1 receptorANTAGONIST
HRH1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(CN1CCN(C2=Nc3ccccc3Oc3ccccc32)CC1)C(=O)O- Mol. weight
- 379.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314393 ↗
- ChEMBLCHEMBL3545287 ↗
Also known as
- hy-10275
- hy-10275
- ly2624803
- ly2624803
- ly2624803
- ly-2624803
- ly-2624803
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01257178 | Phase 1 | Nov 1, 2010 | Eli Lilly |
| NCT01236105 | Phase 1 | Oct 1, 2010 | Eli Lilly |
| NCT01784614 | Phase 1 | Sep 1, 2009 | Eli Lilly |
| NCT00784875 | Phase 2 | Oct 1, 2008 | Eli Lilly |
| NCT01779830 | Phase 1 | May 1, 2008 | Eli Lilly |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 5 | 5 | 2 | 2008 |
1 organizations
Page 1 / 1